An overview of the LASER-AD study: A longitudinal epidemiological study of people with Alzheimer's disease by Hoe, J. et al.
Hoe, J., Cooper, C. & Livingston, G. (2013). An overview of the LASER-AD study: A longitudinal 
epidemiological study of people with Alzheimer's disease. International Review of Psychiatry, 25(6), 
pp. 659-672. doi: 10.3109/09540261.2013.838152 
City Research Online
Original citation: Hoe, J., Cooper, C. & Livingston, G. (2013). An overview of the LASER-AD 
study: A longitudinal epidemiological study of people with Alzheimer's disease. International 
Review of Psychiatry, 25(6), pp. 659-672. doi: 10.3109/09540261.2013.838152 
Permanent City Research Online URL: http://openaccess.city.ac.uk/16528/
 
Copyright & reuse
City University London has developed City Research Online so that its users may access the 
research outputs of City University London's staff. Copyright © and Moral Rights for this paper are 
retained by the individual author(s) and/ or other copyright holders.  All material in City Research 
Online is checked for eligibility for copyright before being made available in the live archive. URLs 
from City Research Online may be freely distributed and linked to from other web pages. 
Versions of research
The version in City Research Online may differ from the final published version. Users are advised 
to check the Permanent City Research Online URL above for the status of the paper.
Enquiries
If you have any enquiries about any aspect of City Research Online, or if you wish to make contact 
with the author(s) of this paper, please email the team at publications@city.ac.uk.
1 
 
An overview of the Laser-AD study: a longitudinal epidemiological study of people 
with Alzheimer’s disease (AD) 
 
Authors: 
Juanita Hoe, MSc, PhD*   
University College London 
Email: j.hoe@ucl.ac.uk 
 
 
Claudia Cooper, MRCPsych, PhD 
University College London 
Email:  claudia.cooper@ucl.ac.uk 
 
 
Gill Livingston, FRCPsych, MD 
University College London 
Email: g.livingston@ucl.ac.uk 
 
 
*Address for corresponding author: 
UCL Mental Health Sciences Unit 
University College London 
Charles Bell House  
67 – 73 Riding House Street  
London  
W1W 7EJ  
 
Telelphone: (+44) 7462813257 
Fax: 020 7679 9426 
  
2 
 
Abstract 
Research into the epidemiological, clinical characteristics and economic impact of dementia 
is critical to increase understanding and better inform care and policy, and empower people 
with Alzheimer’s disease (AD) and their families to make preparations and timely decisions  
about accommodation, care and treatment.  The LASER-AD longitudinal study of people 
with AD and their carers, has contributed to our understanding of the progression, 
characteristics and costs of the disease, and to developing tools that help detect dementia 
earlier, screen and identify problems experienced by carers.  Our work on quality of life 
showed that even those with severe dementia could report this meaningfully, although family 
proxy-ratings of quality of life do not necessarily mirror the views of the individual.  Despite 
the impact of the disease process people with AD experience wellbeing in adversity and still 
live fulfilling lives. The study highlighted the high prevalence and severity of neuropsychiatric 
symptoms, carer anxiety, depression and abusive behaviour. It informed future directions for 
possible interventions, in particular, the central role of carer coping strategies in predicting 
carer mental illness. Current research is building on our findings, which have also been used 
to inform national and international plans for managing people with dementia and their 
carers. 
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An overview of the Laser-AD study: a longitudinal epidemiological study of people 
with Alzheimer’s disease (AD) 
 
Introduction:   
There are currently 820,000 people living with dementia in the UK and this is rising, as the 
population ages (Jorm et al., 1987; Luengo-Fernandez et al, 2010). Dementia is a complex 
disorder, which affects the individual, their family and society. In brief, dementia is a 
progressive neurological disease characterised by loss of memory and ability to self-care. 
Mood changes and problems with communication, judgement and decision-making also 
occur frequently. Neurospsychiatric symptoms are common in dementia and are associated 
with carer distress, diminished quality of life for both individuals and their carers, and the 
breakdown of care (Ballard et al., 2004; Coen et al., 1997; Lyketsos et al., 2002), due to 
more rapid cognitive decline and premature institution (Cohen et al., 1993; Muraman et al., 
2002; Rapoport et al., 2001).  Research into the epidemiological, clinical characteristics and 
economic impact of dementia is critical to increase understanding and thus to inform better 
care and policy and empower people with Alzheimer’s disease (AD) and their families to 
make preparations and timely decisions about accommodation, care and treatment.  
In this review, we present an overview of the findings of the London and the South East 
Region (LASER-AD) study of the UK.  The LASER-AD study was a 54 month, longitudinal 
epidemiological study of 224 people with AD and their carers. In the LASER-AD study, we 
investigated predictors of progression, institutionalisation and mortality in AD, costing models 
for AD, symptoms of AD, quality of life (QoL) and ageing well in adversity, as well as issues 
affecting carers of people with AD, including, psychological morbidity, attachment, coping, 
safety and elder abuse. 
 
 
Study description 
The relevant local research ethics committees gave approval for the study and informed 
consent was sought from all participants. If the patient with AD could not give informed 
consent, they were asked for assent and the caregiver was asked for their consent. 
Interviews with people with AD and their carers were usually carried out in the participant’s 
home. Participants were purposively recruited and we sought to ensure they were 
representative of people with AD in terms of severity of cognitive impairment, gender and 
living situation (Fratiglioni et al., 1998).  Inclusion criteria were: diagnosis of possible or 
probable AD (APA, 2008; McKhann et al., 1984), aged ≥55 years, living in either North 
London or Essex and having a family or statutory carer for ≥4 hours a week. Interviews were 
conducted by trained health professionals. Demographic data was collected and 
standardised instruments measured cognition, functional status, neuropsychiatric symptoms, 
quality of life and resource use. Physical examination and relevant blood tests were 
performed and all prescribed medication recorded.  Follow-up interviews occurred at 6, 18, 
30, 42 and 54 months. 
 
There are 25 publications from the LASER-AD study and the details of individual papers are 
given in Table 1.  The areas examined in this cohort of 224 people with AD and their carers 
include disease detection (Mahoney et al., 2005); predictors of progression (Fox et al., 2011; 
Livingston et al., 2007; Regan, et al., 2006), institutionalisation (Habermann et al., 2009) and 
mortality in AD (Paradise et al., 2009); costing models for AD (Livingston et al., 2004, Rive et 
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al., 2010a; Rive et al., 2010b); symptoms of AD (Train et al., 2004; Regan et al., 2005; Ryu 
et al., 2005) and characteristics of moderate-severe AD (Livingston et al., 2006); quality of 
life (Hoe et al., 2005; Hoe et al., 2007) and ageing well in adversity (Livingston et al., 2008). 
The issues affecting carers of people with AD, include psychological morbidity (Livingston et 
al., 2005; Maidment et al., 2005), attachment (Cooper et al., 2008a), coping (Cooper et al., 
2006; Cooper et al., 2008b; Cooper et al., 2008c), safety in AD (Walker et al., 2006), carer 
attributions of behaviour in AD (Paton et al., 2004) and elder abuse in AD (Cooper et al., 
2008d). 
 
 
Disease detection in Alzheimer’s disease 
With the number of people with dementia rising as the population ages (Blansjaar et al., 
2000), there is a need for a more sensitive and specific screening tool to aid early detection 
and diagnosis of dementia. Currently the most widely used screening test is the Mini-Mental 
State Examination (MMSE: Folstein et al., 1975). The MMSE is quick and easy to perform 
and requires no informant or specialist equipment, but it has a pronounced ‘ceiling effect’ 
(De Jager et al., 2002) and can fail to detect cognitive impairment in individuals with high 
pre-morbid ability or education (Huppert et al., 1995; Cullum et al., 2000). The TE4D (Test 
for the Early Detection of Dementia from Depression, also known as the TFDD; Ihl et al., 
2000) was developed in Germany to differentiate early dementia from depression.  Mahoney 
et al., (2005) modified this test for use in an English-speaking population and hypothesised 
that the TE4D-Cog would be more sensitive and specific than the MMSE in detecting mild 
cognitive impairment in people with AD. The TE4D has excellent validity, reliability and 
discriminative ability between people with and without early dementia. At cutpoint ≥35, 
TE4D-Cog had 100% sensitivity and 84.0% specificity. It is also quick to administer, 
acceptable, easy to score and can detect change. The TE4D-Cog may therefore be a useful 
alternative to the MMSE as a dementia screening instrument. 
 
 
Predictors of disease progression in Alzheimer’s disease 
Regan et al., (2006) investigated the relationship of vascular risk to the progression of AD, 
and examined whether people with AD who have vascular risk factors have a worse 
prognosis over 18 months than those without such risk factors.  Clinical and biochemical 
indicators of vascular disease were not associated with rate of decline in cognition, 
neuropsychiatric symptoms, or functioning in AD over 18 months in people with AD who 
have a low burden of cerebrovascular risk factors.  There was no difference in rate of 
deterioration between people with and without vascular risk factors. Treatment with statin 
medication, aspirin, or calcium channel blockers was also not associated with deterioration. 
However, having a cerebrovascular accident during the 18-month follow-up period 
contributed considerably to the rate of deterioration in cognition and functioning along with 
stopping acetylcholinesterase-inhibitors (AChEIs).  
 
Livingston et al., (2007) undertook a comparison of those taking antipsychotic drugs for more 
than 6 months compared with those who were not, in terms of change in three measures of 
cognition and whether in naturalistic circumstances where those who do badly may stop 
antipsychotics, as opposed to randomised controlled trials. The effects of potential mediators 
and confounders (demographic factors, neuropsychiatric symptoms, cognitive severity and 
AChEIs) were examined.  Greater baseline cognitive severity was the only predictor of 
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further cognitive decline. Although taking antipsychotics was associated with increased 
mortality, this was accounted for by greater age and cognitive impairment. Those people 
taking any or only atypical antipsychotics, over 6 months, were no more likely to decline 
cognitively than those who were not.  An increased dose did not correlate with greater 
cognitive decline, suggesting no causative relationship between cognitive decline and 
antipsychotic prescription. Although clinicians should remain cautious when prescribing 
antipsychotic drugs to people with AD and only do so when the person is experiencing 
considerable distress and other treatments have not worked, these results suggest that, any 
increase in cognitive deterioration was not of the magnitude previously reported. 
 
There is increasing evidence that anticholinergic medications may adversely affect cognitive 
function (Han et al., 2008; Tune 2001).  These are used in a variety of conditions, for 
example psychiatric conditions, cardiac disease and bladder illnesses and people with 
dementia take these medications because of multiple illness comorbidities (Schubert et al., 
2006).  People with AD may be at particular risk of cognitive deterioration secondary to 
medication with anticholinergic effects because of marked reduction in the functioning of 
central cholinergic pathways (Pakashi & Kalman, 2008). Fox et al., (2011) examined the 
impact of medications with anticholinergic effects on cognitive impairment and deteriorat ion 
in AD.  Cognition was measured using three measures of cognitive function at three time-
points: baseline, 6 and 18 months follow-up. ‘Anticholinergic burden’ scores were calculated 
using the Anticholinergic Burden scale (ABS: Boustani et al., 2008; Campbell et al., 2009, 
2010) and included all prescribed and over the counter medication.  The mean number of 
medications taken was four and the mean anticholinergic load was one. The total number of 
drugs taken and anticholinergic load correlated (p<0.01).  There were no differences in 
cognition for any of the three measures (ADAS-COG, MMSE and SIB) at either 6 or 18 
months after adjusting for baseline cognitive function, age, gender and use of AChEIs 
between those with, and those without high anticholinergenic load.  Psychotropics were the 
commonest group of medications recorded with anticholinergic effects. The lack of an effect 
of anticholinergic burden may be because of the decreased sensitivity of people with more 
advanced cognitive impairment, or due to prolonged use of anticholinergic medication, or 
that any impact on cognitive function had occurred prior to enrolment in the study. 
Alternatively, medications with anticholinergic effects may not be as damaging to cognition 
as first thought in established AD. 
 
 
Predictors of institutionalisation in Alzheimer’s disease  
Advancing dementia is one of the principal indicators for placement in long-term care 
settings and up to 90% of people with dementia are reported to enter an institution prior to 
death (Yaffe et al., 2002).  Knowledge about predictors of entering care homes can enable 
policy makers to make accurate predictions about the need for future provision of care 
homes (Hope et al., 1998) and also inform the development of interventions to delay care 
home entry (McCann et al., 2005).  
 
Haberman et al., (2009) examined a comprehensive range of carer and people with AD 
characteristics collected over 54 months to identify predictors of entering 24-h care. The 
mean time to 24-h care entry was 19 months.  The main independent predictors of shorter 
time to enter 24-h care were the participants being: more cognitively or functionally impaired 
and having a paid versus a family carer, the carer being less educated and spending less 
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hours caring.  In contrast with other studies (Luppa et al., 2008; Yaffe et al., 2002), the 
people with AD’s behavioural symptoms and carer burden were not found to be significant 
predictors. People with AD cared for by their partner stayed longest at home, followed by 
those cared for by other family or friends, while those whose carer was paid entered 24-h 
care earliest. Interventions to improve impairment in people with AD’s may have benefits for 
their health and allow them to remain at home longer. This financial benefit could more than 
offset the treatment cost. 
 
 
Predictors of mortality in Alzheimer’s disease  
AD is associated with variable but shortened life expectancy, even at relatively early stages 
(Ganguli et al., 2005; Wolfson et al., 2001). Many people with mild to moderate disease die 
unexpectedly early, while others live more than a decade. Consistently reported 
determinants of shortened survival are increasing age (Burns et al., 1991; Brookmeyer et al., 
2002), male sex (Jagger et al., 1995; Larson et al., 2004) and disease severity (Bowen et al., 
1996; Moritz et al., 1997).  Greater knowledge about predictors of survival may develop our 
understanding of AD. It could also empower people with AD and their families to make 
preparations and timely decisions about accommodation, care and treatment. Unfortunately, 
clinicians currently have limited information with which to advise about survival time, 
particularly for those with milder disease who still die unexpectedly early (Ganguli et al., 
2005). 
 
Paradise et al., (2009) investigated predictors of mortality in people with mild or moderate 
AD (the derivation cohort) for 42 months and tested these on a separate validation cohort. 
Independent determinants of shorter survival were identified and from these the SAM 
(Survival in Alzheimer’s Model) was developed.  The four-point risk scale according to 
whether an individual had none, one, two or all three of the identified risk factors, was tested 
on a validation cohort of 241 consecutive memory clinic patients who fulfilled the criteria for 
mild to moderate AD and had undergone a full physical examination.  Baseline 
constructional apraxia, age and gait apraxia independently predicted shorter survival.  More 
than 80% of those without any of these risk factors survived at least three and a half years, 
while only around a third of those with three risk factors survived this long. Survival was not 
associated with the prescription of antipsychotic or antidepressant medication, in agreement 
with Livingston et al., (2007) who found that antipsychotic medication was not associated 
with cognitive decline or survival. There is a clear difference in the survival time of people 
with mild or moderate AD according to their possession of the identified risk-factors. The 
SAM is a potentially useful tool for clinicians who previously had very limited specific and 
quantitative prognostic information to tell people with AD and their carers. This model 
predicted survival from age, constructional and gait apraxia. This may be because 
constructional and gait apraxia are relatively free from educational or cultural bias and thus 
are better indicators of severe neuropathology than global cognitive tests. Alternatively, they 
may increase falls or immobility, or represent disease sub-types with worse prognoses. 
 
 
Costing models for Alzheimer’s disease 
Economic evaluations of chronic progressive diseases, such as AD, typically rely on 
modelling techniques because clinical trials are often too short to measure long-term 
outcomes of treatment alternatives. While cognitive impairment is a major clinical feature, on 
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its own it is a poor predictor of disease severity. Other manifestations of AD progression, 
such as the worsening of a person’s ability to perform day-to-day activities and behavioural 
disturbances are also important, resulting in a greater need for long-term institutional care 
and increased healthcare expenditure (Jonsson et al., 2006; Small et al., 2002; Zhu et al., 
2006). The symptomatology and duration of AD, and costs associated with care of 
dependent people with AD; make it an extremely challenging disease for the individual, 
carers and society as a whole. Institutionalisation is the largest component of the direct costs 
of AD (Hux et al., 1998; Trabucchi et al., 1999).  An alternative approach to modelling AD 
progression and the cost-effectiveness of pharmacological treatments for AD is based on a 
person with AD’s need for full-time care. This is defined in terms of the amount of 
supervision and care required by a person with AD on a daily basis, regardless of the locus 
of care and who the carer is.  Data from the LASER-AD data was used to establish costing 
models for AD looking at dependency, predictors to full time care and treatment with 
memantine for moderate to-severe AD. 
 
Livingston et al., (2004) validated a qualitative method for classifying disability in AD within a 
UK community setting using basic and instrumental activities of daily living and to examine 
the potential relationship between dependency and care costs. Three clusters with different 
levels of functional disability (‘dependent’, ‘non-dependent’ or ‘nondependent but with 
instrumental functional disability’) were identified.  The cost of caring for people with AD was 
driven by functional ability, a surrogate and measurable marker of independence. The 
relationship between costs and disability levels was not, however, linear suggesting that 
there is a threshold of dependency above which people with AD are relatively low users of 
health and social care services. Therefore, treatments that enable people to remain above 
this threshold may save resources.  The ability to qualitatively classify people according to 
functional disease stage will have future usefulness for assessing and monitoring people 
with AD, allowing more accurate identification of assistance needs and potentially delaying 
institutionalisation. 
 
Rive et al., (2010a) developed a model to predict the length of time before people with AD of 
varying severity require full-time care.  Using the classification of dependency established in 
Livingston et al., (2004), participants who were dependent and/or institutionalised were 
considered to require full-time care; non-dependent and non-institutionalised participants 
were assumed to be pre-full-time care.  The model identified the rate of deterioration and 
reflected differences in disease progression.  Rive et al., (2010a) found that baseline 
cognitive impairment, functional disability and behavioural disturbances were strong 
predictors of time to full-time care. In addition, the rate of cognitive decline and functional 
impairment predicted time to full-time care. The predictive model presented is useful for 
future studies, as it enables the effects of pharmacological interventions in AD to be 
identified and examined over a longer-term perspective. 
 
Delay of full-time care is clinically and economically relevant for decision makers, carers and 
people with AD. Particularly in people with very advanced AD, evaluating the impact of 
treatment based on the time taken to reach a more severe state is no longer appropriate; 
time to full-time care represents the most, and perhaps only, relevant outcome for people 
with advanced AD and their carers.  Rive et al., (2010b) undertook a cost-utility analysis to 
assess the cost effectiveness of memantine in the UK healthcare setting.  The model 
simulated 5-year progress of people with AD until they need full-time care, defined as a 
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person becoming either dependent or institutionalised. Transition probabilities were based 
on the predictive equation established in Rive et al., (2010a). Two major data sources were 
combined: a meta-analysis of six large multicentre randomised controlled clinical trials for 
memantine (Winblad et al., 2007), and data from the LASER–AD study. Treatment with 
memantine prolonged time to full-time care on average by 6 weeks per participant compared 
to standard care over the 5–year evaluation period, representing a 7% increase in the time 
to full-time care compared to standard treatment. Memantine was also associated with a 
gain of 0.031 QALY (Quality Adjusted Life Years) compared to routine care. The health 
benefits with memantine translated into cost savings that completely offset the additional 
cost of memantine above that of standard care. The treatment is therefore associated with 
increased benefits at no additional costs relative to its alternative, and can be regarded as a 
cost-effective treatment choice for the management of moderate and severe AD. 
 
 
Neuropsychiatric symptoms 
In the LASER-AD study, we investigated the prevalence, persistence and change in 
neuropsychiatric symptoms in people with mild, moderate and severe AD, and their 
relationship to prescriptions of psychotropic drugs and exercise.   
 
 Ryu et al., (2005) found that three-quarters of participants experienced neuropsychiatric 
symptoms and that these were usually clinically significant and persistent over 6 months 
(80%). Those with less severe symptoms were more likely to improve. Overall, deterioration 
in neuropsychiatric symptoms was predicted by deterioration in MMSE scores. We did not 
find an association between neuropsychiatric symptoms and specific psychiatric treatments, 
probably due to under-treatment and the complexity of symptoms. Clinically significant 
neuropsychiatric symptoms were associated with greater costs of care.  Train et al., (2004) 
found that more neuropsychiatric symptoms, and in particular hallucinations and aberrant 
motor behaviour were associated with greater cognitive impairment. Antipsychotics were 
more likely to be prescribed with lower MMSE scores, while AChEIs were less likely.  
 
Previous evidence has shown that exercise protects against depression in older adults 
(Mather et al., 2002; Teri et al., 2003). Regan et al., (2006) investigated the relationship of 
exercise and other risk factors to depression in AD and found that regular exercise may 
protect against depression.  Exercise levels were classified into three categories: absent, 
moderate, and vigorous, using the previous two weeks exercise levels to confirm regularity 
and recency. Independent predictors of depression were: lack of exercise, taking AChEIs 
and having less involvement in hobbies or interests. People who took any exercise were less 
likely to be depressed than those that were sedentary. These findings in people with AD are 
consistent with previous studies showing that exercise is protective against depression 
across the age range (Lawlor & Hopker, 2001). We did not find evidence to support the 
theories that the development of depression in AD is linked directly to vascular pathology, 
measured using the Hachinski Ischaemic score (Hachinski et al., 1975), or to retention of 
insight (in terms of milder impairment).  
 
 
Characteristics of people with severe and moderately severe Alzheimer’s disease  
The progression of AD is conventionally divided into three stages: mild, moderate and 
moderately severe–severe and evaluation is based on global, cognitive, functional and 
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behavioural disabilities. In the LASER-AD study, Livingston et al., (2006) collected 
information about moderately severe and severe AD participants (MMSE<15) over 6 months 
and compared them to those at an earlier stage in the disease. Several neuropsychiatric 
symptoms were more frequent and/or severe in moderately severe–severe participants. 
However, after 6 months, no significant behavioural changes were observed in any of the 
three severity groups and anti-psychotic prescription did not change either. Globally, total 
health and social service resource use were lower in the more advanced stages, possibly 
due to participants being institutionalised and not requiring home care services. But carer 
time increased significantly after 6 months for all participants and at all severity levels. Even 
at the later stages of AD, participants show varying rates of decline.  While moderately 
severe and severe participants are more often dependent than less severe participants, they 
are not homogeneous and differ considerably in their needs and abilities. Therefore, 
moderately severe and severe participants can be regarded as being amenable to 
intervention and have the potential to experience varying and even high levels of QoL.  
Moreover, this decline increases burden on carers.  
 
 
Quality of life in Alzheimer’s disease 
Health Related Quality of Life (HRQoL) is particularly important in chronic, degenerative 
disorders such as dementia because of the limited relevance of outcomes such as 
symptoms and survival rates (Jonnson et al., 2000). The person with dementia’s subjective 
ratings of QoL are the gold standard for measuring QoL but these may be difficult to elicit 
and of questionable validity, particularly in severe dementia where observational ratings may 
be more useful (Novella et al., 2001). In the LASER-AD study, we explored the self ratings of 
QoL in severe dementia and comparisons of self and proxy ratings of QoL and the concept 
of wellbeing in adversity. 
 
Hoe et al., (2005) examined the ability of people with severe dementia to rate their own QoL 
using the Quality of Life in Dementia Scale (QOL-AD: Logsdon et al., 1999).  It is known that 
people with mild to moderate dementia can provide valid assessments of their own QoL, but 
it was unclear whether these instruments are useful in those with severe dementia.  We 
found evidence for the validity and reliability of the QOL-AD in people with MMSE scores of 
3–11, and that it was possible for most individuals with a score of 3 or more on the MMSE to 
rate QoL meaningfully using the QOL-AD. The findings showed (counter-intuitively) that QoL 
does not decrease as cognition worsens and that QoL ratings were influenced by the 
person’s mood. This challenges the commonly-held assumption that worsening dementia is 
associated with worse QoL.   Hoe et al., (2007) then compared self-ratings of QoL for people 
with dementia with proxy-ratings by family carers. Although highly correlated, there were 
also important differences.  As with earlier studies, QoL was rated lower by family carers 
than by the individual (Logsdon et al., 1999; Sands et al., 2004; Selai et al., 2001).  Fewer 
depressive symptoms, living at home and taking AChEIs predicted higher ratings of QoL in 
people with dementia.  Clinicians should therefore be aware that proxy-ratings do not 
replicate the person with dementia’s views of QoL, although they give important and 
consistent information. 
 
 
Wellbeing in adversity 
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Successful ageing may not only be about escaping illness but also having a positive attitude 
towards one’s life despite poor health (Depp & Jeste, 2006).  ‘‘Successful ageing’’ is often 
defined as the absence of physical and cognitive impairment, usually neglecting the 
possibility of positive adaptation or resilience in the face of health related adversity and is 
most closely related to being younger (Depp & Jeste, 2006). This implies that successful 
ageing is deficit based, and does not include older people who may be living ‘‘successfully’’, 
with some degree of impairment. Many people with chronic conditions consistently rate their 
own quality of life highly (Albrecht & Devlieger, 1999).  This ‘‘disability paradox’’ highlights 
the multidimensional nature of QoL, which encompasses emotional, social and psychological 
as well as health related domains (Albrecht & Devlieger, 1999; Vogel et al., 1006). Livingston 
et al., (2008) examined the predictors of successful ageing, or wellbeing in adversity, in 
people with AD using a self-rated, single item ‘‘life as a whole’’ measure. Mean ‘‘wellbeing in 
adversity’’ scores did not change significantly over time, and future wellbeing was directly 
predicted by mental health (anxiety and depression) and social relationships rather than by 
either global dementia severity or general health. These factors fully mediated the 
relationship found between health perception and wellbeing 18 months later.  This 
contradicts the earlier literature that defined ‘‘successful ageing’’ as lack of illness.  The 
measure of ‘‘wellbeing in adversity’’ was not related to age.  
 
 
Carers for people with Alzheimer’s disease  
As the number of people with AD increases, so too does the number of carers (Blansjaar et 
al., 2000).  Family carers provide the majority of care for people with dementia, (Baumgarten 
et al., 1992) and they experience significantly higher levels of psychological morbidity, 
depression, stress, and burden than people who are not carers or who are caring for 
physically ill relatives (Brodaty et al., 1990; Eagles et al., 1987; Livingston et al., 1996; Morris 
et al., 1988). Data from the LASER-AD study was used to look at psychological morbidity, 
attachment, coping and knowledge in family carers. 
 
 
Carer psychological morbidity 
Family carers of people with dementia experience high rates of stress, distress, and 
psychological illness. Various factors are associated with carer “burden” and “stress,” such 
as being a woman, having a poor relationship with the person with AD, lack of social support, 
and the person with AD having dementia (Burns & Rabin, 2000; Pinquart & Sorenson, 2003; 
Oyebode, 2013).  Sources of stress may vary according to the carer’s own situation: 
Spouses, being older, may experience strain due to physical or financial problems, whereas 
adult children may have conflicting responsibilities, such as work or children (Oyebode, 
2013).  Maidment et al., (2005) found nearly a quarter of carers of people with AD 
interviewed for the LASER-AD study screened positive for anxiety and 10% for depression. 
Carer anxiety was significantly predicted by the carer being female, living with the person 
with AD, rating the quality of their relationship as poor, having poor perceived health, and the 
care-recipient’s level of dependency. Higher irritability scores and the carer’s perception of 
poor health strongly predicted depression. We concluded that clinicians should be alert for 
risk factors for anxiety and depression; specifically, additional difficulties, such as carer poor 
health, the quality of the relationship between the carer and the person with AD, and 
irritability in the person with AD, because these are potentially modifiable. 
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Livingston et al., (2005)  developed the Carers for Alzheimer’s Disease Problems Scale 
(CAPS) comprising common risk factors for anxiety and depression for family carers of 
people with dementia. The CAPS was tested in a representative sample of people with AD 
and their carers and had high sensitivity and specificity in detecting carers with screen 
positive anxiety and depression. The five areas identified as predictors were: 
neuropsychiatric symptoms and depression in the care-recipient, co-residence and 
relationships with the care-recipient, and physical health of the carer. The CAPS is the first 
screening tool to enable clinicians to identify rapidly those dementia carers at risk of having 
significant anxiety or depressive symptoms and its use as part of the routine assessment 
may be helpful. 
 
As the evidence shows the quality of the carer- care-recipient relationship predicts those 
carers most at risk from anxiety, Cooper et al., (2008a) examined the relationship of 
attachment styles to anxiety in carers of people with dementia. The Attachment 
Questionnaire (Hazan and Shaver, 1987; 1990) was used to measure the participant’s 
subjective attachment style (secure, avoidant and anxious/ambivalent). Most carers reported 
that their main attachment style was secure, but more avoidant attachment and less secure 
attachment predicted anxiety. Carers who were less secure, or who had a more avoidant 
attachment style, reported higher anxiety, and that this relationship was partially mediated by 
their greater use of dysfunctional coping strategies. Furthermore a proportion of anxiety was 
independent of carer burden and coping, and may relate to circumstances extraneous to 
caring. Carers are therefore likely to benefit from interventions that aim to modify use of 
coping strategies. 
 
 
Coping in family carers 
Coping is a process by which people manage stress.  Cooper et al., (2006) investigated the 
relationship of anxiety with coping strategies in family carers of people with dementia.  
Coping strategies were classified as problem-focused, emotion-focused and dysfunctional 
(Carver et al., 1997). Problem-focused coping strategies involve defining a problem, 
generating alternative solutions and considering their relative costs and benefits. Emotion-
focused strategies seek to lessen the emotional distress associated with a situation through 
trying to change one’s feelings about it.  Depression and greater use of dysfunctional coping 
strategies were the only factors which independently predicted anxiety.  Addressing coping 
strategies may therefore be helpful for managing carer anxiety.  The Brief COPE is a self-
completed questionnaire measuring coping strategies. Cooper et al., (2008b) investigated 
the validity and reliability of the COPE and its dysfunctional, problem-focused or emotion-
focused subscales in carers of people with dementia.  We found evidence for good internal 
consistency and construct validity and the brief COPE demonstrated sensitivity to change for 
the problem-focused and dysfunctional coping scales. Change in emotion-focused coping 
was correlated with change in other types of coping but not burden. Using these Brief COPE 
subscales in clinical research was recommended, as the measures reflect the components 
of potential therapeutic interventions needed. In a subsequent paper, we found using 
emotion-focussed coping strategies in response to carer burden seemed to protect carers 
from developing higher anxiety levels a year later; however using problem-focused 
strategies did not (Cooper et al., 2008c). Use of dysfunctional coping was related to higher 
anxiety score and most of those who were anxious at baseline remained anxious 1 year later. 
Successful caregiving for people with degenerative disease probably involves using 
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problem-focussed coping strategies where situations can be changed, and adapting 
emotionally when they cannot. Especially in later stages of caring, many of the problems 
which carers face are likely to be intractable and therefore responding to them with problem-
focused strategies may prove frustrating and ineffective. Implementing psychological 
interventions to emphasise emotion-focused coping may help to reduce anxiety in dementia 
carers.  
 
 
Safety in Alzheimer’s disease 
Within the LASER-AD study, Walker et al., (2006) explored safety issues in dementia from a 
carer’s perspective. Even when the level of dementia is mild, carers generally feel it is 
unsafe to leave the person with AD alone. The majority of carers (80%) took their own 
measures to keep the person with AD safe.  Despite this, most (70%) reported at least one 
incident occurring in the last year which posed a significant risk to the person with AD. 
Walker et al., (2006) found the number of risk minimisation strategies implemented was 
neither related to the number of risk incidents nor to carer morbidity. We concluded that 
there is inevitably a level of risk associated with having dementia and living in the community, 
and both carers and professionals have to accept that, albeit infrequently, the person with 
AD will be in danger. Risk reducing measures are not absolute guarantees and can be 
regarded as analogous to harm minimisation strategies used to decrease risk for other 
mental health problems. 
 
 
Carer attributions of behaviour in Alzheimer’s disease 
There is little research exploring what carers think is the cause of problem behaviour in 
people with dementia.  Paton et al., (2004) found attributions regarding problematic 
behaviours were extremely varied and the majority of carers did not attribute symptoms to 
AD despite being aware of the diagnosis. Many believed that the symptoms were under the 
persons’ control and some that the person with AD would improve. As in other studies, short-
term memory loss was identified most frequently by carers as problematic (Whitehouse & 
Chamberlain, 2000). Many other symptoms were difficult for carers to deal with, for example, 
aggression, apathy, hallucinations, delusions and anxiety were often identified as troubling. 
Aggression was only rarely attributed to AD, more often it was attributed to other factors 
such as childhood experiences or premorbid personality. Whilst it is plausible that 
aggression could be rooted in such factors, it is likely that AD may be a contributory factor. 
That carers tend not to attribute symptoms to AD, suggests they have a different 
understanding of dementia, or are trying to minimise or deny the effects of illness, and often 
think that information given is not applicable to their situation. This has implications for 
clinicians working with people with dementia and carers in this area, especially regarding the 
nature and presentation of information about dementia. Education by clinicians should focus 
on the understanding of carers and, in particular, explore and come to a mutual 
understanding of the symptoms, control and prognosis specifically focusing on the person for 
whom they care. 
 
 
Elder abuse in Alzheimer’s disease 
Detecting elder abuse accurately is important but inherently difficult, as it is often perpetrated 
against vulnerable people by those they rely on, and few elder abuse measures are 
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validated.  In the LASER-AD study, Cooper et al., (2008d) investigated the acceptability and 
validity of the Modified Conflict Tactics Scale (MCTS), and compared carer self-report and 
observer-rated elder abuse screens for the first time.  Of eighty-six people with AD and their 
family carers interviewed, 24(27.9%) were identified as abuse cases using the self-report 
MCTS. The MCTS was acceptable and had convergent and discriminant validity for 
measuring carer abuse. By contrast, the observer-rated Minimum Data Set Abuse screen 
(MDS-A) failed to identify any cases of abuse. Carer burden, being a male carer and caring 
for someone who was less functionally impaired but with more cognitive impairment and 
irritability predicted carer reports of abuse.  Asking family carers about abuse is therefore 
more likely to lead to its detection and earlier studies have underestimated the prevalence of 
abuse and its link to carer stress.  Furthermore, the findings appeared to refute the UK 
government elder abuse reduction policy of the time which assumed that few incidents of 
abuse arises from carer stress. 
 
 
Conclusion  
The LASER-AD longitudinal study of people with AD and their carers has been very 
influential over the past 12 years.  It has contributed to our understanding of the progression, 
characteristics and costs of the disease. The work on quality of life showed that people with 
dementia often rate this highly, and showed for the first time that even those with severe 
dementia could report this meaningfully. We reported that family proxy-ratings of QoL do not 
necessarily mirror the views of the individual, even in the severe stages of the disease.  We 
found that despite the impact of the disease process people with AD experience wellbeing in 
adversity and still live fulfilling lives. The study highlighted the high prevalence and severity 
of neuropsychiatric symptoms, of carer anxiety, depression and abusive behaviour.  It 
informed future directions for possible interventions, such as the central role of carer coping 
strategies in predicting carer mental illness and by indicating the link between exercise and 
better outcomes. The study also contributed to the development of tools that help detect 
dementia earlier and screen and identify the specific problems experienced by carers. Work 
continues to try to help more people with AD and their carers experience high quality of life.  
Current research that builds on our findings include a clinical trial of a manualised based 
coping strategy programme to promote better mental health in carers of people with 
dementia (START: Strategies for Relatives) and a longitudinal study into the epidemiology 
and risk factors for elder abuse in dementia (CARD: Caring for Relatives with Memory 
Disorders). Furthermore, data from the LASER-AD contributed to the Technology 
Assessment Report (NICE, 2011) which reviewed the clinical and cost effectiveness of 
antidementia medication and allowed AChEIs to be prescribed for people with early AD.  Our 
findings have also contributed to national health and social care guidelines for managing and 
supporting people with dementia and their carers (NICE-SCIE, 2012). In addition, the 
LASER-AD study had been used to inform international plans to address Alzheimer’s 
disease and elder abuse in the USA (US Department of Health and Human Services, 2013; 
Nakhnikian, 2011) and in Europe (Soares et al., 2010). 
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